CNTB News and Press, Connect Biopharma Holdings Limited From 03/17/23

ePoster and Oral Presentation at American Academy of Dermatology Annual Meeting Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, ...

2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

CBP-201 global AD data accepted as an e-Poster with an Oral Presentation CBP-201 China AD trial data accepted as a late-breaking Oral Presentation Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical compan...

SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting on...

Summary The Ulcerative Colitis trial is the sole clinical catalyst in H1 2023. It will likely succeed, although the drug candidate has no future without a partner. Plan B is still the lead drug CBP-201 in China's atopic dermatitis market. For further details se...

U.S. and China-based biotech Connect Biopharma ( NASDAQ: CNTB ) has delayed a global Phase 3 program for its lead candidate CBP-201 in atopic dermatitis (AD), the company announced Friday, citing macro concerns and funding challenges as reasons. Previously, the program was expected to...

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress ...

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced th...

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or ho...

Summary Lead product candidate CBP-201 had a successful pivotal trial. After an initial surge, traders selling the news brought prices 15% below the previous close. CBP-201 is now on a near-certain path to approval in the world's 2nd largest market. (Editor's Note:...